Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Acalabrutinib in Severe Hepatic Impairment
NCT03968848Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Acerta Pharma. Primary endpoints: Plasma Acalabrutinib PK Parameters at 72 hours and Maximum Plasma Acalabrutinib Concentration at 72 hours. Started Nov 2018; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03968848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968848.